Literature DB >> 2327990

Differential interactions of human kallikrein-binding protein and alpha 1-antitrypsin with human tissue kallikrein.

L M Chen1, L Chao, R K Mayfield, J Chao.   

Abstract

The characteristics of a new kallikrein-binding protein in human serum and its activities were studied. Both the kallikrein-binding protein and alpha 1-antitrypsin form 92 kDa SDS-stable and heat-stable complexes with human tissue kallikrein. In non-SDS/PAGE, the mobility of these complexes differ. Complex-formation between kallikrein and the binding protein is inhibited by heparin, whereas that between kallikrein and alpha 1-antitrypsin is heparin-resistant. In normal or alpha 1-antitrypsin-deficient-serum, the amount of 92 kDa SDS-stable complex formed upon addition of kallikrein is not related to serum alpha 1-antitrypsin levels. The rate of complex-formation between kallikrein and the binding protein is 12 times higher than that between kallikrein and alpha 1-antitrypsin. Purified alpha 1-antitrypsin, which exhibits normal elastase binding, has a kallikrein-binding activity less than 5% of that of serum. Binding of tissue kallikrein in serum is not inhibited by increasing elastase concentrations, and elastase binding in serum is not inhibited by excess tissue kallikrein. A specific monoclonal antibody to human alpha 1-antitrypsin does not bind to either 92 kDa endogenous or exogenous kallikrein complexes isolated from human serum. The studies demonstrate a new tissue kallikrein-binding protein, distinct from alpha 1-antitrypsin, is present in human serum.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2327990      PMCID: PMC1131247          DOI: 10.1042/bj2670079

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  27 in total

1.  Enhanced specificity in immunoscreening of expression cDNA clones using radiolabeled antigen overlay.

Authors:  S Chao; L Chao; J Chao
Journal:  Biotechniques       Date:  1989-01       Impact factor: 1.993

2.  Isolation and properties of human plasma alpha-1-proteinase inhibitor.

Authors:  R Pannell; D Johnson; J Travis
Journal:  Biochemistry       Date:  1974-12-17       Impact factor: 3.162

3.  Characterization and origin of immunoreactive glandular kallikrein in rat plasma.

Authors:  W J Lawton; D Proud; M E Frech; J V Pierce; H R Keiser; J J Pisano
Journal:  Biochem Pharmacol       Date:  1981-07-01       Impact factor: 5.858

4.  Radioimmunoassay of rat submandibular gland kallikrein and the detection of immunoreactive antigen in blood.

Authors:  K Nustad; K Gautvik; T Orstavik
Journal:  Adv Exp Med Biol       Date:  1979       Impact factor: 2.622

5.  The radioimmunoassay of human urinary kallikrein and comparisons with kallikrein activity measurements.

Authors:  K Shimamoto; J Chao; H S Margolius
Journal:  J Clin Endocrinol Metab       Date:  1980-10       Impact factor: 5.958

6.  Human urinary kallikrein. Complete amino acid sequence and sites of glycosylation.

Authors:  H S Lu; F K Lin; L Chao; J Chao
Journal:  Int J Pept Protein Res       Date:  1989-04

7.  Progressive inhibition of human glandular (urinary) kallikrein by human serum and identification of the progressive antikallikrein as alpha 1-antitrypsin (alpha 1-protease inhibitor).

Authors:  R Geiger; U Stuckstedte; B Clausnitzer; H Fritz
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1981-03

8.  A major difference of kallikrein-binding protein in spontaneously hypertensive versus normotensive rats.

Authors:  J Chao; L Chao
Journal:  J Hypertens       Date:  1988-07       Impact factor: 4.844

9.  Kallikrein localization in rodent salivary glands and kidney with the immunoglobulin-enzyme bridge technique.

Authors:  J A Simson; S S Spicer; J Chao; L Grimm; H S Margolius
Journal:  J Histochem Cytochem       Date:  1979-12       Impact factor: 2.479

10.  Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma.

Authors:  D M Tollefsen; D W Majerus; M K Blank
Journal:  J Biol Chem       Date:  1982-03-10       Impact factor: 5.157

View more
  5 in total

Review 1.  Protective Role of Kallistatin in Vascular and Organ Injury.

Authors:  Julie Chao; Grant Bledsoe; Lee Chao
Journal:  Hypertension       Date:  2016-07-18       Impact factor: 10.190

2.  Kallistatin ameliorates influenza virus pathogenesis by inhibition of kallikrein-related peptidase 1-mediated cleavage of viral hemagglutinin.

Authors:  Chia-Hsing Leu; Mei-Lin Yang; Nai-Hui Chung; Yen-Jang Huang; Yu-Chu Su; Yi-Cheng Chen; Chia-Cheng Lin; Gia-Shing Shieh; Meng-Ya Chang; Shainn-Wei Wang; Yao Chang; Julie Chao; Lee Chao; Chao-Liang Wu; Ai-Li Shiau
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

3.  Specificity of human tissue kallikrein towards substrates containing Phe-Phe pair of amino acids.

Authors:  D C Pimenta; J Chao; L Chao; M A Juliano; L Juliano
Journal:  Biochem J       Date:  1999-04-15       Impact factor: 3.857

4.  Expression and characterization of rat kallikrein-binding protein in Escherichia coli.

Authors:  J X Ma; L Chao; G Zhou; J Chao
Journal:  Biochem J       Date:  1993-06-15       Impact factor: 3.857

5.  Elevated tissue kallikrein activity in airway secretions from patients with tracheobronchitis associated with prolonged mechanical ventilation.

Authors:  T G O'Riordan; M D Weinstein; W M Abraham; R Forteza
Journal:  Lung       Date:  2003       Impact factor: 2.584

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.